Skip to main content
Premium Trial:

Request an Annual Quote

DNAPrint, Genomics Collaborative to Study Pharmacogenomics of Chemotherapy Response

NEW YORK, Nov. 14 (GenomeWeb News) - DNAPrint Genomics and SeraCare Life Sciences' Genomics Collaborative division plan to identify genetic factors associated with how cancer patients respond to carboplatin/tamoxifen-based chemotherapy, DNAPrint said today.


The alliance will study 200 women to compare responses to a standard carboplatin/tamoxifen regimen for breast cancer, according to Hector Gomez, chairman and chief medical officer of DNAPrint.


"We anticipate that the study's findings may enable physicians to identify likely non-responders before initiation of carboplatin/tamoxifen therapy so that an alternative treatment can be utilized from the outset," Kevin Krenitsky, senior vice president and division head of Genomics Collaborative, said.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.